Skip to Main Content

Paper Details

FDA Approval Summary: Fam-Trastuzumab Deruxtecan-Nxki for the Treatment of Unresectable or Metastatic HER2-Positive Breast Cancer.
Clin Cancer Res
62
2021
Author NameAffiliation
Julia A BeaverCenter for Drug Evaluation and Research
Julia A BeaverOncology Center of Excellence
  • 1 - 2

Datasets

Release 1.2